S ymptomatic atherosclerotic vertebrobasilar disease is responsible for approximately one third of posterior circulation strokes 1 and is associated with a high rate of recurrent stroke despite medical therapy. 2 Relatively overlooked compared with the anterior circulation, advances in interventional endovascular therapies have revitalized interest in the treatment of symptomatic vertebrobasilar disease. Although recent randomized studies involving angioplasty and stenting have demonstrated prohibitive periprocedural risks, 2, 3 case series suggest that submaximal angioplasty, which aims to reduce but not fully correct stenosis, seems to have a favorable safety profile. [4] [5] [6] [7] [8] [9] A distinct relationship between distal flow status and risk of subsequent stroke in symptomatic vertebrobasilar disease was identified in the prospective VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke) study. 10 Measurement of posterior circulation flow status by quantitative magnetic resonance angiography (qMRA) identified a high-risk subgroup of low flow patients with a significantly elevated stroke risk, 22% versus 4% at 1 year. 10 
Background and Purpose-The VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and
Stroke) study demonstrated posterior circulation distal flow status, determined by quantitative magnetic resonance angiography, is a robust predictor of vertebrobasilar stroke risk in patients with symptomatic atherosclerotic vertebrobasilar disease. Flow-compromised high-risk patients may benefit from flow-restoring endovascular procedures, such as submaximal angioplasty. In this study, we examine the cost-effectiveness of quantitative magnetic resonance angiography screening to identify patients who may benefit from submaximal angioplasty to restore vertebrobasilar flow. Methods-A Markov model was created comparing a no screening strategy with standard medical management alone and a screening strategy involving quantitative magnetic resonance angiography imaging and submaximal angioplasty for treatable patients with low vertebrobasilar flow for a 30-year time horizon. Outcomes included quality-adjusted life years (QALY) and lifetime costs. Rates of stroke and death were obtained from VERiTAS data, and disability rates and costs were derived from VERiTAS and the literature. A sensitivity analysis was performed with periprocedural stroke rate from angioplasty the primary variable of interest. Results-At a 6% periprocedural stroke risk, the screening strategy saved an average of 0.364 QALYs per patient and a lifetime cost savings of $7312 versus the no screening strategy. Among patients with low flow suitable for intervention, the benefit was substantially higher, averaging 1.485 QALYs saved and lifetime cost savings of $21 294. Across the entire cohort, QALY savings were observed at the end of the first year and economic savings at year 6. The benefit of screening declined at higher periprocedural risk. 
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These patients are potential candidates for endovascular therapies aimed at restoring blood flow. The long-term benefits of decreased stroke risk from submaximal angioplasty must be weighed against the periprocedural risk of the technique, however, as well as the economic costs of the procedure itself. In this study, we sought to examine if a strategy of qMRA screening for patients with vertebrobasilar disease followed by submaximal angioplasty in selected patients with low flow would be cost effective while considering a range of potential periprocedural risks for the intervention.
Materials and Methods
Patient Cohort
The patient population used in this study consisted of all 72 eligible, enrolled patients from the VERiTAS 10 study. VERiTAS patients were enrolled between July 2008 and July 2013 at 5 academic hospitalbased centers in the United States and Canada. The details of the VERiTAS study inclusion criteria are published elsewhere 10 but in brief consisted of patients with posterior circulation transient ischemic attack or stroke attributable to ≥50% atherosclerotic stenosis or occlusion of the intracranial or extracranial vertebrobasilar arteries, based on computed tomographic angiography or conventional digital subtraction angiography. Posterior circulation flow status, as measured by phase contrast qMRA, and outcomes, including fatal and nonfatal vertebrobasilar territory stroke events and functional status outcome metrics were used for model generation. Project approval was obtained through each participating center's institutional review board. A written informed consent was provided by each participant for inclusion in VERiTAS; there was no financial compensation. The authors declare that all supporting data are available within the article, its online-only Data Supplement files, and references.
Model
To determine the cost-effectiveness of qMRA screening and submaximal angioplasty for eligible patients, we created a Markov statetransition model for the 72 VERiTAS patients with symptomatic vertebrobasilar stenosis (Figure 1) . A lifetime 30-year time horizon was used to account for death and costs related to stroke and aging with 1-year cycles. Ten-and 20-year time horizons were also evaluated. Analysis was performed using spreadsheet software (Excel, Microsoft Office Professional Plus 2013, Microsoft Corp, Redmond, WA).
Management Strategies
Two management strategies were considered for VERiTAS patients: (1) a no screening strategy involving no qMRA imaging on patient presentation, and (2) a screening strategy involving qMRA imaging of all patients and selective submaximal angioplasty in low flow patients amenable to intervention. Patients in either strategy were assumed to have maximal medical management after their presenting event.
Health States
Patients were categorized into 1 of 3 health states at each 1-year cycle: alive, current health termed healthy, stroke, and death. At each cycle, patients in the healthy state would exhibit a certain likelihood of transitioning to the stroke state based on yearly VERiTAS event rates ( Figure 1 ). Death rates for healthy patients in each cycle were calculated as the sum of the baseline mortality rate from actuarial tables during the study period 11 and 20% of patients transitioning to the stroke state during the cycle. The 20% rate was derived from the 20% case fatality rate of patients with stroke in VERiTAS, 10 which closely resembles mortality rates for posterior fossa strokes in several large stroke databases. [12] [13] [14] Patients in the stroke state during subsequent cycles exhibited a risk of moving into the death category equal to 2.03× the baseline mortality rate, 11 representing the significantly higher standardized mortality ratio in stroke survivors as compared with the general population. This higher death rate is derived from the Danish MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) study, a registry of long-term survival of ≈3000 stroke survivors. 15 A weighted average of standardized mortality ratios for the ≥70 years age group was selected to reflect the mean VERiTAS patient age of 68 years to obtain the standardized mortality ratio of 2.03. Patients in the death state remained in the death state through all subsequent cycles.
Low Flow and Normal Flow Risk
In VERiTAS, an elevated stroke risk was identified in patients with low vertebrobasilar flow status versus normal flow status for a 2-year period. 10 From this data, a yearly stroke risk was identified for the first 2 cycles for both the low flow and normal flow groups and then extrapolated for the remaining cycles assuming the underlying time variable was continuous. In the full VERiTAS cohort, 75% of patients were found to have normal vertebrobasilar flow and 25% low flow. Of the low flow population, three fifths of patients (15% of the entire cohort) had lesions classified as Mori A or Mori B type and were considered suitable for submaximal angioplasty. The remaining, classified as Mori C (ie, diffuse disease >1 cm, excessive proximal tortuosity, extremely angulated segment ≥90°, complete occlusion), were considered to have anatomy unsuitable for the procedure. 16 In the no screening strategy, healthy to stroke transition probabilities were identified by calculating the average stroke probability for each cycle, based on the probabilities of stroke in the overall VERiTAS cohort. (1) alive, current health, (2) stroke survivor, and (3) dead. During each year cycle, patients had a certain probability of transitioning from alive to stroke or dead, or from stroke to dead based on yearly risks observed in VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke) for the first 2 years or extrapolated from VERiTAS thereafter. Screening and no screening strategies were compared. In the screening strategy, flow status was identified by quantitative magnetic resonance angiography (qMRA), and intervenable low flow patients underwent submaximal angioplasty to restore stroke risk to the same as normal flow after an initial procedural event rate. In the no screening strategy, the flow status remained unknown, and stroke risk remained stable to the baseline proportion of normal and low flow patients in the population. Transition probabilities were carried across 30 cycles for the 30-year time horizon to identify quality-adjusted life years and cost totals for each strategy.
In the screening strategy, the healthy to stroke transition probability was calculated considering that a proportion of the population (15%) was low flow and suitable to treatment. Patients in this group underwent angioplasty on day zero, representing a procedure during the same hospitalization as the qualifying diagnosis, and were classified with normal flow yearly stroke risk thereafter. A one-time stroke risk was added to the first cycle of these patients to represent procedural risk plus an additional 2% to represent risk of stroke from restenosis. 17 The procedural stroke rate from angiography and angioplasty was studied as a variable of interest; a 6% periprocedural risk was targeted based on meta-analysis of studies of submaximal angioplasty for vertebrobasilar stenosis, and a range up to 12% was examined based on highest risks for vertebrobasilar submaximal angioplasty reported in individual case series. [4] [5] [6] [7] [8] [9] For the remainder of the patients in the screening strategy, the healthy to stroke transition probability was calculated based on the risk of stroke for normal flow in the cycle year for the proportion in the normal flow group (initially 75%) and on the risk of stroke for low flow in the cycle year for the proportion in the low flow group, but not amenable to angioplasty intervention (10%).
Quality of Life Estimates
Quality-adjusted life years (QALY) were calculated for each cycle by multiplying the probability of being in a given state (healthy, stroke, death) by a fixed utility value and summing the 3 states together.
Fixed utility values were identified using functional outcome data from VERiTAS and the systematic reviews as follows: a utility of 0.9 was selected for alive, current health healthy patients, representing the weighted average baseline modified Barthel Index of the VERiTAS cohort, 18/20 (0.9), the mild disability of patients who had the transient ischemic attack or stroke necessary for study inclusion, and several systematic reviews. 18, 19 A utility of 0.7 for patients with stroke was selected from systematic reviews for moderate stroke. 10, 19 Patients in the death state had a utility of 0. Total QALYs for each state were summed across the 30-year horizon, and a 3% annual discount was applied to obtain the final total QALY value for both the no screening and screening strategies.
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Cost Estimates
Societal costs (in 2017 dollars) were estimated for each management strategy using the consumer price index change for healthcare to historical price estimates. 21 qMRA screening and angioplasty costs were added as one-time expense to the first cycle of all patients in the screening group. Repeat qMRA costs were added at 6 months and yearly to all living patients with low flow suitable to intervention (15% of the cohort) in the screening group to represent follow-up imaging for restenosis, as in clinical practice. qMRA price ($493.19) was obtained from the mean 2017 Medicare payment for code 70546, the billing code used for VERiTAS screening. Angioplasty costs were added as a one-time expense in the first cycle for patients with low flow suitable for intervention. Angioplasty cost estimates were derived based on the episode of care by calculating the mean difference in 2015 Medicare payments, which represent the most recent publicly available payments, for ischemic stroke admissions using analogous diagnosis-related group codes involving angioplasty versus no angioplasty. A total 2015 marginal angioplasty admission cost of $26 593.27 was derived from the cost of admission with angioplasty ($38 046.40), coded as diagnosis-related group 023, minus the cost for stroke admissions without angioplasty ($11 453.13), coded as diagnosis-related group 064.
Initial, first-year stroke costs were estimated by multiplying new stroke (previously healthy) patients at each cycle by historical mean costs for stroke care during the first year, including hospitalization. 22 Chronic stroke costs were estimated by multiplying all patients in the stroke health state for >1 year (≥2 cycles) by historical mean yearly costs for chronic stroke care. 23 Expenses from death, including funeral home and burial costs, were derived from historical estimates as a one-time cost added on patient death. 18 Economic costs from lost work time/productivity because of death or disability were not considered in the model given the mean age of patients. Mean death, acute stroke, and chronic stroke costs were summed together for each cycle, and all cycles totaled together across the 30-year time horizon to identify the mean lifetime cost for both the no screening and screening strategies, with qMRA and angioplasty costs added to the screening strategy groups.
Sensitivity Analyses
Sensitivity analyses were performed to identify specific variables and their effects on QALYs saved and cost-effectiveness. Input variables and their sources are identified in Table 1 . Except for the cost of death, all cost estimates were derived from large ischemic stroke studies and databases. The procedural stroke risk from angioplasty was studied as the primary variable of interest and measured across a 30-year time horizon to identify QALY and cost-effectiveness at different time points. Analyses were performed for the low flow intervenable patient cohort exclusively to simulate the ideal population (Table 2) . Patients in the screening and no-screening strategies exhibited divergent health states at different time points (Figure 2) . Most of the differences between the proportion of patients in the healthy and stroke states were observed by 5 years although the 2 strategies continued to diverge until 10 years, when, on average, 5 more patients in the screening group (24 versus 19) were healthy versus the no-screening group. At the 6% periprocedural stroke rate, a QALY advantage was observed at the end of the first year for the screening strategy and economic savings at the end of year 6 (Figure 3 ), representing the point at which the higher costs of stroke care in the no screening group outweighed the cost of qMRA and angioplasty in the screening group. These differences continued to diverge until ≈20 years, after which both plateaued.
A sensitivity analysis was performed to identify patients who may benefit from qMRA screening and submaximal angioplasty at different life expectancies and periprocedural stroke rates (Tables I-III in the online-only Data  Supplement) . Several benchmark values are illustrated in Table 3 . The screening strategy generated a net gain in QALYs after only 1 year up to a 9% periprocedural event rate and a net gain after 3 years at the highest event rate studied, 12%. Cost savings were identified as early as 5 years for event rates of 1% or less and at latest 7 years at the 12% event rate maximum. Using a $50 000 per QALY threshold, 24 the screening strategy was found to be cost effective at life expectancies of ≥4 years at a periprocedural event rate of ≤5%, at 5 years for event rates from 6% to 10%, and at 6 years for event rates from 11% to 12%.
Discussion
In VERiTAS, a robust relationship between distal flow status and risk of stroke in vertebrobasilar disease was identified, with low flow patients, as measured on qMRA, having significantly increased risk of stroke. 10 In this study, we examined a strategy of qMRA screening in patients with symptomatic occlusive vertebrobasilar disease and submaximal angioplasty in suitable candidates. Different periprocedural event rates for the intervention were reviewed to assess if screening would yield a gain in QALYs and economic savings. Results from this analysis reveal that a qMRA screening strategy yields improvements in QALY as early as the first year, is economically efficient (<$50 000/QALY) by the end of the fifth year, and returns cost savings by the end of the sixth year for all but the highest periprocedural event rates. The benefit of screening increased further with patient life expectancy but was more modest at higher periprocedural event rates.
The cost-effectiveness of qMRA screening was primarily driven by the high risk of stroke in patients with untreated low flow, with a cumulative incidence of 22% in the first year and 30% by the second, versus 4% and 13% with normal flow, 10 as well as a modest periprocedural risk of angioplasty (6%). These findings suggest that qMRA screening is clinically beneficial and cost effective and should be considered in patients with symptomatic occlusive vertebrobasilar disease.
Cost-Effectiveness of Screening and Treatment for Occlusive Cerebrovascular Disease
Previous studies have demonstrated the cost-effectiveness of procedures and mixed results for screening in occlusive cerebrovascular disease. Following the NASCET (North American Symptomatic Carotid Endarterectomy Trial) 25 and CREST (Carotid Revascularization Endarterectomy vs Stenting Trials), 26 cost-effectiveness studies demonstrated clinical benefit of both carotid endarterectomy 27, 28 and carotid artery stenting 29 with modest costs or savings versus medical management alone and with similar results between the at a lifetime time horizon. These benefits for carotid disease were evident in patients already identified and selected for the surgical intervention; the analogous population in our study would be the selected low flow, intervenable cohort, where the benefit of identification and treatment compares favorably to that seen for treatment of symptomatic carotid disease, at a benefit of 1.485 QALYs and $21 294 in cost savings (Table 2) .
After potential benefits of treatment were identified in the ACAS (Asymptomatic Carotid Artery Stenosis) 31 trial, a subsequent cost analysis identified that screening carotid ultrasound was somewhat cost effective but dependent on disease prevalence. 32 In patients with a high prevalence (20%) of ≥60% carotid stenosis, one-time screening yielded a mean gain of 0.03 QALYs per patient, at a cost of $35 130 per QALY gained ($75 863 in 2017 dollars), while in a low disease prevalence (4%) population, the gain was more modest, at 0.007 QALYs per patient, at a cost of $52 588 per QALY gained ($113 663 in 2017 dollars). 32 Critical, then, is finding a high-risk population suitable for screening to maximize the yield of a potential test. As demonstrated in VERiTAS, patients with a recent posterior circulation transient ischemic attack or stroke meet this criterion, with 25% of screened patients having low flow and 15% having treatable disease, yielding a gain of 0.364 QALYs and cost savings ( Table 2 ). These findings illustrate the potential benefits of screening for hemodynamic compromise in untreated symptomatic vertebrobasilar disease.
Submaximal Angioplasty
The cost-effectiveness of screening for vertebrobasilar disease in this study was driven primarily by the high stroke rate in untreated, low flow patients and high costs for yearly stroke care. Although the proportion of patients screened amenable to treatment was relatively low, at 15%, the cost benefit of screening and treating this high-risk population was able to compensate for the modest price of qMRA screening ($493) for the entire cohort. Although the up-front cost of angioplasty is relatively high ($28 347), decreased long-term stroke care costs for the low flow population yields cost savings for the entire group by year 6, on average.
The intervention assessed in this study, submaximal angioplasty, seems to have a favorable safety profile in recent case series, with vertebrobasilar stroke event rates ranging from 0% to 12%, 4-9 but warrants further investigation. Although the screening strategy remained cost effective even at the upper limit of periprocedural risk, it is important to consider that the relative risk reduction in stroke is typically the means by which interventions are measured in comparative trials. For intracranial atherosclerotic disease, a majority of practitioners indicate that a ≥40% relative risk reduction from an intervention for intracranial stenosis would be considered impactful. 33 In low flow vertebrobasilar stenosis patients, a procedural risk of 6% would be expected to translate into an overall 12% 1-year stroke risk, considering a base 4% stroke risk in normal flow patients 10 and 2% risk of stroke attributable to restenosis 17 ; this yields a >40% relative risk reduction compared with the natural history risk of 22% at 1 year. 10 However, a 12% periprocedural risk would translate into an 18% estimated Figure 3 . Quality-adjusted life years (QALY), lifetime costs, screening vs no screening strategies. A QALY benefit was observed in the screening strategy (white circles) vs the no screening strategy (black circles) at the end of the first year while an economic benefit was observed at the end of year 6. The economic benefit at 6 years represents when the initial cost of quantitative magnetic resonance angiography and angioplasty is outweighed by the higher costs of stroke care in the no screening group. 1-year stroke risk, representing a <20% relative risk reduction which would not warrant a comparative trial. Given both the projected clinical efficacy and cost savings associated with screening if periprocedural risk is similar to reported pooled rates (ie, 6%), 34 a study to definitively identify the periprocedural risk of the intervention is warranted.
An important limitation of the current study is that data from the prospective VERiTAS cohort were only measured up to 2 years. With relatively short follow-up periods typical in stroke risk studies, 25, 26, 31 this is not ideal for modeling studies, 27, 29, 32 which frequently rely on projected data for long-term outcomes. This article is no exception, with stroke rates beyond 2 years extrapolated from trends in VERiTAS and the literature and may not represent true long-term stroke risk. Nevertheless, VERiTAS is the only prospective study of recurrent stroke risk in vertebrobasilar disease of its type, with long-term data on stroke recurrence rare, particularly for the posterior circulation. Furthermore, the first 2 years of data were derived directly from observed data in VERiTAS and is responsible for a proportionally large fraction of the total QALY (20%) and costs (14%) across the 30-year time horizon. Another limitation is the moderate sample size of the VERiTAS cohort. This may affect the generalizability of the results and necessitates a deterministic study design, limiting the ability to make probabilistic estimates of event rates, although this is not uncommon in cost-effectiveness studies.
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Conclusions
This study demonstrates that qMRA screening and selective submaximal angioplasty would be both clinically effective and cost saving in patients with symptomatic vertebrobasilar occlusive disease if the procedure can be performed effectively and safely with a presumed risk of 6%. The benefit of screening and submaximal angioplasty is primarily driven by a high risk of stroke in untreated low flow patients and modest periprocedural risk. The projected benefits are similar to those found in cost-effectiveness studies in the carotid literature. With potential health and economic savings, a clinical trial examining the periprocedural risk and the efficacy of submaximal angioplasty is warranted.
